Source comparison
How Does Sermorelin Compare to Other Research Peptides: Peptide Comparison
Sermorelin Acetate GHRH receptor agonist. Stimulates pituitary GH release 10–20 minutes Physiological pulsatility enhanced Yes. Somatostatin retains suppressive function GH axis dynamics, age-related GH decline models, metabolic studies requiring intact feedba
This comparison does not assign a generated winner or score.
- Sermorelin Acetate
- GHRH receptor agonist. Stimulates pituitary GH release
- 10–20 minutes
- Physiological pulsatility enhanced
- Yes. Somatostatin retains suppressive function
- GH axis dynamics, age-related GH decline models, metabolic studies requiring intact feedback
- Best choice when endogenous regulation must remain intact; lower amplitude but higher fidelity to natural physiology
- GHRP-2 / GHRP-6
- Ghrelin receptor agonist. Bypasses somatostatin suppression
- 60–90 minutes
- Large-amplitude pulses, reduced trough depth
- Partial. Overrides somatostatin during active window
- Acute GH secretion studies, appetite regulation research, combination protocols with GHRH analogs
- Higher peak GH than sermorelin; appetite stimulation complicates metabolic models; synergistic when combined with GHRH agonists
- Ipamorelin
- Selective ghrelin receptor agonist. Minimal cortisol/prolactin co-release
- 2–3 hours
- Sustained elevation across multiple pulses
- Partial. Longer duration reduces pulsatile fidelity
- Growth and recovery models, protocols requiring minimal HPA axis activation
- Cleaner side-effect profile than GHRP-2/6; longer half-life reduces injection frequency but distorts natural pulse timing
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist. Chronic GHS-R activation
- 24+ hours
- Near-continuous tonic elevation
- No. Suppresses endogenous pulsatility entirely
- Chronic GH exposure studies, sarcopenia models, oral administration protocols
- Eliminates injection requirement; sustained elevation mimics exogenous hGH pharmacokinetics; insulin resistance and appetite increase limit long-term metabolic research
- Synthetic hGH (rhGH)
- Exogenous growth hormone. Bypasses pituitary entirely
- 3–4 hours (subcutaneous)
- Tonic elevation with no pulsatility
- No. Suppresses GHRH and upregulates somatostatin
- Severe GH deficiency models, growth plate research, supraphysiological GH exposure studies
- Gold standard for maximum GH exposure; completely shuts down endogenous axis; requires extended washout for axis recovery
- This table reflects comparative data from preclinical GH secretion studies and pharmacokinetic analyses published in endocrinology literature. Sermorelin's shorter half-life and preserved feedback make it the most conservative intervention. Ghrelin agonists trade regulatory fidelity for higher amplitude. Synthetic hGH is the most aggressive option, appropriate only when dismantling endogenous regulation is acceptable.